Navigation Links
First human trial of antibacterial contact lens

Biotechnology company Biosignal Ltd and the Institute for Eye Research have received ethics approval for the first human clinical trial of an antibacterial extended-wear contact lens.

The ASX-listed company commercialises a novel anti-bacterial technology identified by UNSW researchers at the Centre for Marine Biofouling and Bioinnovation.

The trial beginning on June 29 will compare the safety performance of an antibacterial contact lens to that of a standard contact lens.

The comparison involving ten people will evaluate eye health, lens performance on the eye and wearers' subjective responses. Biosignal will announce the trial's results to the market in July.

"Adverse events caused by microbial contamination of contact lenses are a major impediment to more convenient, extended wear of contact lenses," says UNSW Professor Mark Willcox, who will supervise the trial. "This trial is the first significant step towards overcoming this significant problem."

Acute red eye occurs in 20 per cent per year of the estimated 100 million wearers of contact lenses worldwide. Microbial keratitis, a serous eye disease that can cause blindness, occurs in one in 500 contact lens wearers per year if they sleep in lenses. There is currently no antibacterial contact lens in the market.

Biosignal's technology prevents and disrupts microbial infection by "jamming" the signalling systems bacteria rely on to form biofilms. Because the technology does not kill bacteria, Biosignal's technology is less likely to create the drug-resistance problems that plague current anti-microbial treatments. The US Centers for Disease Control estimate that biofilms account for at least two-thirds of all chronic bacterial infections.

Biosignal and the Institute for Eye Research have tested antibiofilm compounds and generated proof of concept data in a broad range of product categories in the medical, industrial and consumer
'"/>

Source:University of New South Wales


Page: 1 2

Related biology news :

1. Timing is everything: First step in protein building revealed
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
6. First real-time view of developing neurons reveals surprises, say Stanford researchers
7. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
8. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
9. First frozen egg baby born in Canada
10. Human Cells Filmed Instantly Messaging for First Time
11. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First human trial antibacterial contact lens

(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... a class of small molecules known as microRNA have been ... in most animal and plant species. A new study now ... a hallmark of alcohol abuse and dependence. Researchers supported by ... the findings in the July 31 issue of the journal ...
... July 29, 2008 Two Fortune 500 oil companies ... Engineering at the University of Houston. The funds, from ... Corp., will provide support for a new undergraduate program ... by the Texas Higher Education Coordinating Board this fall. ...
... or cold is not only uncomfortable, it can be ... many years now, scientists have understood the molecular mechanisms ... extremely high temperatures that directly trigger heat sensor proteins ... understood is how animals sense very small temperature differences ...
Cached Biology News:MicroRNA implicated as molecular factor in alcohol tolerance 2Energy industry leaders commit $1.6M to UH petroleum program 2Energy industry leaders commit $1.6M to UH petroleum program 3Summer heat too hot for you? What is comfortable? 2Summer heat too hot for you? What is comfortable? 3
(Date:6/2/2015)... GenoCAD , a platform leveraging the ... announced the formation of its new board of advisors ... a broad range of experience in the biotechnology, pharmaceutical, ... , Jimmy Roussel, Entrepreneur in Residence at The New ... technology and marketing. He has served in operations roles ...
(Date:6/1/2015)... 2015 Research and ... addition of the "Oxidative Stress Assay ... Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769) , The global oxidative ...
(Date:6/1/2015)... GenomeDx Biosciences today announced that ... classified various subtypes of bladder cancer based ... including one type associated with resistance to ... has potential as a tool to predict ... with muscle-invasive bladder cancers (MIBC). The study ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
Breaking Biology Technology:GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... 20 At a meeting of the Board,of Directors of ... of fifty cents($0.50) per share on the outstanding shares of ... of record at the close of business,on December 12, 2008. ... of the world,s largest research-driven pharmaceutical and,health care products companies. ...
... 20 Sigma-Aldrich (Nasdaq: SIAL ),announced today ... iScale,Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) ... next step in their RNAi,research with the highest purity ... These siRNA are believed to be well suited to ...
... Nephros, Inc. (Amex: NEP ), a medical device company developing and marketing ... on its operations and strategy. , , Recent ... , Appointed James Scibetta Chairman of ... III President and CEO , Submitted 510k for ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7